From: Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy
Patient characteristics | Patients (n = 65) |
---|---|
Median age, years (range) | 51 (18–84) |
Age group, n (%) | |
  < 60 years | 48 (73.8) |
  ≥ 60 years | 17 (26.2) |
Sex, n (%) | |
 Male | 34 (52.3) |
 Female | 31 (47.7) |
Disease, n (%) | |
 AML | 33 (50.8) |
  De novo AML | 23 (35.4) |
  Secondary AMLa | 10 (15.4) |
 ALL | 31 (47.7) |
  Philadelphia-positive | 3 (4.6) |
  Philadelphia-negative | 28 (43.1) |
 ABL | 1 (1.5) |
 Favorable | 3 (4.6) |
 Intermediate | 29 (44.6) |
 Poor | 30 (46.2) |
 Unknown | 3 (4.6) |
Risk group (AML only), n (%) [1] | |
 Favorable | 3 (9.1) |
 Intermediate | 16 (48.5) |
 Poor | 12 (36.4) |
 Unknown | 2 (6.0) |
Induction chemotherapy, n (%) | |
 AID-based regimen | 30 (46.2) |
 Modified FLAI | 3 (4.6) |
 VPD-based regimen | 30 (46.2) |
 ADVP-based regimen | 2 (3.1) |
Median BM blast percentage at diagnosis (range) | 80.0 (12.9–98.5) |
Median duration of micafungin treatment, days (range) | 24 (1–68) |
Median time from induction chemotherapy to severe neutropenia (ANC < 500/μL), days (range) | 24 (11–84) |